Patents by Inventor Cynthia Bamdad

Cynthia Bamdad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC ANTIGEN RECEPTOR COMPOSITIONS AND METHODS FOR TREATING MUC1* DISEASES
    Publication number: 20240261331
    Abstract: Disclosed herein are chimeric antigen receptors (CARs) that target MUC1*. In some embodiments, the CARs have been optimized to reduce T cell exhaustion.
    Type: Application
    Filed: February 1, 2024
    Publication date: August 8, 2024
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Anti-NME antibody and method of treating cancer or cancer metastasis
    Patent number: 12049514
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: July 30, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method for making pluripotent stem cells
    Patent number: 12049618
    Abstract: The present application discloses a method for inducing cells to gain characteristics of naïve stem cell state comprising culturing the cells in the presence of a MUC1* activator.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: July 30, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • MEDIA FOR STEM CELL PROLIFERATION AND INDUCTION
    Publication number: 20240247229
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Application
    Filed: January 3, 2024
    Publication date: July 25, 2024
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Anti-NME antibody and method of treating cancer or cancer metastasis
    Patent number: 12037413
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: July 16, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Humanized anti-MUC1* antibodies
    Patent number: 12006371
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: June 11, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Diagnostic methods using anti-MUC1* antibodies
    Patent number: 11976132
    Abstract: The present application discloses a method of determining suitability of treating a patient suffering from cancer or metastasis of cancer characterized by aberrant expression of MUC1, with a MUC1* targeting therapeutic.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: May 7, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventor: Cynthia Bamdad
  • Media for stem cell proliferation and induction
    Patent number: 11976295
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: January 12, 2023
    Date of Patent: May 7, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Method of screening for agents for differentiating stem cells
    Patent number: 11931347
    Abstract: The present application discloses a method for identifying an agent for the treatment or prevention of cancer or metastatic cancer comprising the steps of contacting stem cell with a potential agent, and identifying an agent that induces differentiation, or inhibits stem cell pluripotency or growth of the stem cell, wherein such agent is determined to be an anti-cancer agent.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: March 19, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Scott Moe
  • Humanized anti-MUC1* antibodies
    Patent number: 11897967
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: August 4, 2022
    Date of Patent: February 13, 2024
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • MUC1* ANTIBODIES
    Publication number: 20230295340
    Abstract: The present describes monoclonal antibodies.
    Type: Application
    Filed: December 6, 2022
    Publication date: September 21, 2023
    Inventors: Cynthia Bamdad, Sanjeev Mahanta
  • MEDIA FOR STEM CELL PROLIFERATION AND INDUCTION
    Publication number: 20230287338
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Application
    Filed: January 12, 2023
    Publication date: September 14, 2023
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • HUMANIZED ANTI-MUC1* ANTIBODIES
    Publication number: 20230279142
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Application
    Filed: August 4, 2022
    Publication date: September 7, 2023
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS
    Publication number: 20230279141
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: June 8, 2021
    Publication date: September 7, 2023
    Inventors: Cynthia BAMDAD, Benoit SMAGGHE
  • Humanized anti-MUC1* antibodies
    Patent number: 11746159
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 5, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • ANTI-NME ANTIBODY AND METHOD OF TREATING CANCER OR CANCER METASTASIS
    Publication number: 20230242678
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Application
    Filed: June 27, 2021
    Publication date: August 3, 2023
    Inventors: Cynthia BAMDAD, Benoit SMAGGHE
  • METHODS FOR DERIVING DOPAMINERGIC NEURONS FROM PLURIPOTENT STEM CELLS
    Publication number: 20230242874
    Abstract: The present application discloses a method of producing dopaminergic neurons from human stem cells by adding or increasing concentration of vitamin into neuro basal media at approximately Day 20+/?3 of a protocol for differentiating pluripotent stem cells into dopaminergic neurons.
    Type: Application
    Filed: June 28, 2021
    Publication date: August 3, 2023
    Inventors: Cynthia BAMDAD, Kevin R. YI, Scott T. MOE, Thomas JEON
  • Method of treating an NME7 expressing cancer with a peptide
    Patent number: 11702483
    Abstract: The present application discloses anti-NME antibodies and their use in treating or preventing diseases.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: July 18, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • HUMANIZED ANTI-MUC1* ANTIBODIES
    Publication number: 20230183373
    Abstract: The present application discloses humanized antibodies and antibody like proteins and fragments thereof.
    Type: Application
    Filed: August 4, 2022
    Publication date: June 15, 2023
    Inventors: Cynthia Bamdad, Benoit Smagghe
  • Media for stem cell proliferation and induction
    Patent number: 11591565
    Abstract: The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a MUC1* activating ligand.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: February 28, 2023
    Assignee: MINERVA BIOTECHNOLOGIES CORPORATION
    Inventors: Cynthia Bamdad, Benoit Smagghe